We are excited to announce the publication of our latest research, “In vitro and in vivo evaluation of the biofilm-degrading Pseudomonas phage Motto, as a candidate for phage therapy”.
This study introduces Pseudomonas phage Motto, a T1-like phage capable of effectively degrading Pseudomonas aeruginosa biofilms. In vitro experiments demonstrated significant anti-biofilm activity against strong biofilm-producing isolates, achieving at least a twofold reduction within 24 hours. In vivo efficacy was confirmed using a Caenorhabditis elegans model, where phage treatment resulted in a 90% survival rate at a multiplicity of infection of 10. Safety assessments conducted with human cell lines (HEK 293 and RAW 264.7 macrophages) indicated no cytotoxic effects, supporting the potential of phage Motto for therapeutic applications. A heartfelt thank you to the first author, Prasanth, for leading this impactful study. Congratulations to all contributors for this significant advancement in phage therapy research!
The Leptihn Lab 